News

08 Nov 2017

REPROCELL Chooses Science Exchange as the Preferred Partner to Increase Accessibility of its Predictive Drug Discovery Services

Press release: REPROCELL Chooses Science Exchange as the Preferred Partner to Increase Accessibility of its Predictive Drug Discovery Services
Read More >>

08 Nov 2017

Visit REPROCELL at the “North East England Life Science Showcase” in Cambridge, MA (USA) on November 30, 2017

Visit REPROCELL at the “North East England Life Science Showcase” in Cambridge, MA (USA) on November 30, 2017
Read More >>

07 Nov 2017

Prof Stefan Przyborski to chair and speak at SMi Group’s 3D Cell Culture 2018 Conference

REPROCELL Europe Ltd's CSO Prof Stefan Przyborski to chair and speak at SMi Group’s 3D Cell Culture 2018 Conference
Read More >>

27 Sep 2017

Article by Dr David Bunton (co-authored) in the European Pharmaceutical Review, Autumn 2017

REPROCELL Europe Ltd’s CEO, Dr David Bunton, has co-authored an article titled New Strategy that has been published in the European Pharmaceutical Review, Autumn 2017. The article is in the EPR’s section, Applied Research, Development and Production. It is co-authored by David Bunton at REPROCELL Europe, Marian McNeil at Stratified Medicine Scotland and Pamela Brankin at Aridhia.
Read More >>

1 2 3 4 >>

Biopta co-authors research in the European Respiratory Journal

18/11/2015

The impact of fresh human tissue studies for translational work performed at Biopta has once again been demonstrated with this latest publication at the European Respiratory Society.   This abstract describes the biological mechanisms by which a novel chemokine antagonist, AXP1275, impacts lung inflammation through its action at the CCR3-muscarinic M3 receptor heterodimer.  The disease relevance of such biological complexity can only be truly demonstrated in fresh human tissue, in an environment where the receptor and pathway interaction occurs naturally. Click here to access the abstract.

Live chat by BoldChat